UNIverse - Public Research Portal
Project cover

A randomized add-on pilot trial of D-serine for depression

Research Project
 | 
01.03.2021
 - 31.12.2024

The glutamate system is emerging as target for the development of novel antidepressant medication, in particular compounds modulating the NMDA receptor. While the NMDA receptor antagonist ketamine is an effective option for many treatment-restistan patients, it is also accompanied by dissociative and cognitive effects and also bears the risk to develop addiction, side effects that are significantly restricting its clinical utility. There is now compelling evidence of the antidepressant potential of D-serine, a NMDAR co-agonist. Compared to ketamine, D-serine goes along without any psychotomimetic effects or other side effects and thus might be a promising novel antidepressant. This study represents the first randomized control trial to test the efficacy of D-serine as an adjuvant therapy in patients with depression and thereby adds to recent efforts to establish novel glutamatergic antidepressants.

Members (3)

Profile Photo

André Schmidt

Principal Investigator
FEMALE avatar

Annette Brühl

Co-Investigator
Profile Photo

Undine Lang

Co-Investigator